Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-label, Randomized, Controlled Parallel-group Study to Assess Discontinuation Rates, Bleeding Patterns, User Satisfaction and Adverse Event Profile of LCS12 in Comparison to Etonorgestrel Subdermal Implant Over 12 Months of Use in Women 18 to 35 Years of Age.

Next Previous
Trial Profile

Multicenter, Open-label, Randomized, Controlled Parallel-group Study to Assess Discontinuation Rates, Bleeding Patterns, User Satisfaction and Adverse Event Profile of LCS12 in Comparison to Etonorgestrel Subdermal Implant Over 12 Months of Use in Women 18 to 35 Years of Age.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levonorgestrel (Primary) ; Etonogestrel
  • Indications Pregnancy
  • Focus Adverse reactions; Registrational
  • Sponsors Bayer; Bayer HealthCare

Most Recent Events

  • 23 Mar 2016 Results published in the Fertility and Sterility.
  • 09 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
  • 06 May 2014 The trial status is completed in Sweden, as reported by EudraCT.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top